Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.
Crohn's disease
Health-related quality of life
Hospitalization rate
Infliximab
Work productivity/activity impairment
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
06
2020
accepted:
08
10
2020
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
ppublish
Résumé
Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn's disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients' quality of life in an economically sensible way is conflicting so far. We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period ( In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.
Identifiants
pubmed: 33850839
doi: 10.1159/000512159
pii: iid-0006-0048
pmc: PMC8015262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-60Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
N.T. received personal fees from MSD during the study conduct and personal fees from Falk Foundation, Ferring Arzneimittel GmbH, Janssen, AbbVie, and Takeda. M.B., F.H.E., and E.J. received personal fees from MSD during the conduct of the study. A.S. was a consultant for AbbVie, Amgen, Astellas, Falk Foundation, Ferring, MSD, and Takeda and had served as a paid speaker and/or scientific advisor on medical education events supported by MSD. S.H. is an employee of MSD.
Références
Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1130-6
pubmed: 27340897
Can J Gastroenterol. 2011 Sep;25(9):497-502
pubmed: 21912761
J Crohns Colitis. 2015 Nov;9(11):1032-42
pubmed: 26245216
PLoS One. 2016 Apr 21;11(4):e0142481
pubmed: 27099937
Aliment Pharmacol Ther. 2017 Jan;45(1):3-13
pubmed: 27862107
Inflamm Bowel Dis. 2006 May;12(5):402-12
pubmed: 16670530
Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):838-48
pubmed: 21688345
Adv Ther. 2009 Oct;26(10):936-46
pubmed: 19838649
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
pubmed: 20064142
Clin Exp Gastroenterol. 2009;2:101-9
pubmed: 21694833
Scand J Gastroenterol Suppl. 2006;(243):46-54
pubmed: 16782622
Aliment Pharmacol Ther. 2004 Aug 15;20(4):459-67
pubmed: 15298641
J Crohns Colitis. 2019 Sep 19;13(9):1148-1157
pubmed: 30809631
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45
pubmed: 26284562
Gut. 2013 Mar;62(3):368-75
pubmed: 22717453
Value Health. 2002 Mar-Apr;5(2):106-13
pubmed: 11918826
Inflamm Bowel Dis. 2019 Aug 20;25(9):1522-1531
pubmed: 30753510
J Crohns Colitis. 2014 Jul;8(7):590-7
pubmed: 24351733
Inflamm Bowel Dis. 2013 Sep;19(10):2098-110
pubmed: 23860567
J Rheumatol Suppl. 2011 Nov;88:55-61
pubmed: 22045980
Am J Gastroenterol. 2004 Jan;99(1):91-6
pubmed: 14687148
J Crohns Colitis. 2020 Jan 1;14(1):53-63
pubmed: 31076743
Pharmacoeconomics. 2006;24(8):797-814
pubmed: 16898849
J Crohns Colitis. 2014 Aug;8(8):898-9
pubmed: 24434182
Gastroenterology. 2005 Apr;128(4):862-9
pubmed: 15825070
Clin Ther. 2008 Feb;30(2):393-404
pubmed: 18343277
BMJ. 2014 Nov 19;349:g6670
pubmed: 25409896
Gut. 2014 Jan;63(1):72-9
pubmed: 23135759
N Engl J Med. 2004 Feb 26;350(9):876-85
pubmed: 14985485
Gastroenterology. 2008 Nov;135(5):1493-9
pubmed: 18848553
Curr Treat Options Gastroenterol. 2005 Jun;8(3):187-196
pubmed: 15913508
Gut. 2012 Apr;61(4):622-9
pubmed: 22267595
Dig Liver Dis. 2003 Dec;35(12):853-61
pubmed: 14703880
BMC Gastroenterol. 2014 Nov 25;14:199
pubmed: 25421821
J Crohns Colitis. 2013 May;7(4):322-37
pubmed: 23395397
World J Gastroenterol. 2019 Oct 14;25(38):5862-5882
pubmed: 31636478